nach oben

Erschienen in:

01.01.2011 | Original Article

Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma

verfasst von: Izumi Nishimura, Yoshihiro Ohishi, Yoshinao Oda, Junji Kishimoto, Masafumi Yasunaga, Emi Okuma, Hiroaki Kobayashi, Norio Wake, Masazumi Tsuneyoshi

Erschienen in: Virchows Archiv | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

This study was designed to analyze the subcellular localization of E-cadherin and β-catenin both of which play a critical role in cell–cell adhesion in uterine carcinosarcoma (UCS). We performed an immunohistochemical reaction analysis of the subcellular localization of E-cadherin and β-catenin proteins in 46 cases of UCSs consisting of 28 UCSs with heterologous sarcoma and 18 UCSs with homologous sarcoma and compared their clinicopathological features. In most UCSs, membranous expression of E-cadherin and β-catenin was completely lost in sarcomatous components, but it was preserved in carcinomatous components. Nuclear β-catenin expression was observed significantly more frequently in sarcomatous components (31/46, 67.4%) than in carcinomatous components (22/46, 47.8%; P = 0.0025). In sarcomatous components, nuclear β-catenin expression was found significantly more frequently in heterologous sarcoma (23/28, 82.1%) than in homologous sarcoma (8/18, 44.4%; P = 0.0279). The stage was the only independent prognostic significant factor. These results suggest that reduced membranous expression of E-cadherin and β-catenin may contribute to the biphasic morphology of UCS. Furthermore, although the precise mechanism is unclear, nuclear β-catenin expression in sarcomatous components may also be associated with biphasic morphology and heterologous sarcomatous differentiation.

Silverberg SG, Major FJ, Blessing JA et al (1990) Carcinosarcoma (malignant mixed mesodernal tumor) of the uterus. A gynecologic oncology group pathologic study of 203 cases. Int J Gynecol Pathol 9:1–19CrossRefPubMed

Wada H, Enomoto T, Fujita M et al (1997) Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 57:5379–5385PubMed

Emoto M, Iwasaki H, Kikuchi M, Shirakawa K (1993) Characteristics of cloned cells of mixed mullerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro. Cancer 71:3065–3075CrossRefPubMed

Fujii H, Yoshida M, Gong ZX et al (2000) Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 60:114–120PubMed

McCluggage WG (2002) Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 12:687–690CrossRefPubMed

Sreenan JJ, Hart WR (1995) Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 19:666–674CrossRefPubMed

Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31:1653–1661CrossRefPubMed

Goltzmann J, Mikula M, Eger A et al (2004) Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 566:9–20CrossRef

Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2006) Epithelial–mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997CrossRef

10.

Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454CrossRefPubMed

11.

Mayer B, Johnson JP, Leitl F et al (1993) E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 53:1690–1695PubMed

12.

Saito T, Oda Y, Sugimachi K et al (2001) E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features. Am J Pathol 159:2117–2124PubMed

13.

Gumbiner BM (2000) Regulation of cadherin adhesive activity. J Cell Biol 148:399–404CrossRefPubMed

14.

Saito T, Oda Y, Sakamoto A et al (2000) Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of β-catenin mutations in synovial sarcoma. J Pathol 192:342–350CrossRefPubMed

15.

Shimazui T, Schalken JA, Giroldi LA et al (1996) Prognostic value of cadherin-associated molecules (α-, β-, and γ-catenins and p120^cas) in bladder tumors. Cancer Res 56:4154–4158PubMed

16.

Ilyas M (2005) Wnt signalling and the mechanistic basis of tumour development. J Pathol 205:130–144CrossRefPubMed

17.

Tetsu O, McCormick F (1999) β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426CrossRefPubMed

18.

Chen G, Shukeir N, Potti A et al (2004) Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma. Potential pathologenetic and prognostic implications. Cancer 101:1345–1356CrossRefPubMed

19.

Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S (1998) β-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 58:3526–3528PubMed

20.

Saegusa M, Hashimura T, Yoshida T, Okayasu I (2001) β-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 84:209–217CrossRefPubMed

21.

Scholten AN, Creutzberg CL, van den Broek LJCM, Noordijk EM, Smit VTHBM (2003) Nuclear β-catenin is a molecular feature of type I endometrial carcinoma. J Pathol 201:460–465CrossRefPubMed

22.

Kondo Y, Kanai Y, Sakamoto M et al (1999) β-catenin accumulation and mutation of exon 3 of the β-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res 90:1301–1309PubMed

23.

Van Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA (1999) Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155:703–710PubMed

24.

Eger A, Stockinger A, Park J et al (2004) β-catenin and TGFβ signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 23:2672–2680CrossRefPubMed

25.

Moreno-Bueno G, Hardisson D, Sarrio D et al (2003) Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120^ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 199:471–478CrossRefPubMed

26.

Scholten AN, Aliredjo R, Creutzberg CL, Smit VTHBM (2006) Combined E-cadherin, α-catenin, and β-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer 16:1379–1385CrossRefPubMed

27.

Nikaido T, Li SF, Shiozawa T, Fujii S (1996) Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 78:1248–1253CrossRefPubMed

28.

Saegusa M, Hashimura M, Kuwata T, Okayasu I (2009) Requirement of the Akt/β-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of Slug. Am J Pathol 174:2107–2115CrossRefPubMed

29.

Kirchner T, Brabletz T (2000) Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol 157:1113–1121PubMed

30.

Fodde R, Brabletz T (2007) Wnt/β-catenin signaling in cancer stemness and malignant behavior. Cur Op Cell Biol 19:150–158CrossRef

31.

Van Es JH, Barker N, Clevers H (2003) You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 13:28–33CrossRefPubMed

32.

Petropoulos H, Skerjanc IS (2002) β-catenin is essential and sufficient for skeletal myogenesis in P19 cells. J Biol Chem 277:15393–15399CrossRefPubMed

33.

Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH (2004) Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10:55–63CrossRefPubMed

34.

Matsushime H, Ewen ME, Strom DK et al (1992) Identification and properties of an atypical catalytic subunit (p34psk-j3/CDK4) for mammalian D type G1 cyclins. Cell 71:323–334CrossRefPubMed

35.

Ozaki S, Ikeda S, Ishizaki Y et al (2005) Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 14:1437–1443PubMed

36.

Iwasa Y, Haga H, Konishi I et al (1998) Prognostic factors in uterine carcinosarcoma. A clinicopathologic study of 25 patients. Cancer 82:512–519CrossRefPubMed

Titel: Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma
verfasst von: Izumi Nishimura
Yoshihiro Ohishi
Yoshinao Oda
Junji Kishimoto
Masafumi Yasunaga
Emi Okuma
Hiroaki Kobayashi
Norio Wake
Masazumi Tsuneyoshi
Publikationsdatum: 01.01.2011
Verlag: Springer-Verlag
Erschienen in: Virchows Archiv / Ausgabe 1/2011
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-010-1002-9

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Paratesticular fibrous pseudotumor—an IgG4-related disorder?

EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC

Philadelphia: cradle of American pathology

Annex to Quirke et al. Quality assurance in pathology in colorectal cancer screening and diagnosis: annotations of colorectal lesions

Chromosome 3p alterations in pancreatic endocrine neoplasia

Quality assurance in pathology in colorectal cancer screening and diagnosis—European recommendations

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie